Wrapmanager Inc. Has $282,000 Stake in Sanofi (NASDAQ:SNY)

Wrapmanager Inc. lowered its position in Sanofi (NASDAQ:SNY) by 32.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,662 shares of the company’s stock after selling 2,750 shares during the period. Wrapmanager Inc.’s holdings in Sanofi were worth $282,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in SNY. Cardinal Capital Management increased its holdings in shares of Sanofi by 0.3% during the 4th quarter. Cardinal Capital Management now owns 58,854 shares of the company’s stock valued at $2,927,000 after acquiring an additional 201 shares during the last quarter. Daiwa Securities Group Inc. raised its position in shares of Sanofi by 3.4% in the fourth quarter. Daiwa Securities Group Inc. now owns 6,541 shares of the company’s stock valued at $325,000 after purchasing an additional 216 shares during the period. Gallacher Capital Management LLC lifted its stake in shares of Sanofi by 4.5% in the third quarter. Gallacher Capital Management LLC now owns 5,715 shares of the company’s stock worth $307,000 after buying an additional 245 shares during the last quarter. Rise Advisors LLC lifted its stake in shares of Sanofi by 98.4% in the fourth quarter. Rise Advisors LLC now owns 506 shares of the company’s stock worth $25,000 after buying an additional 251 shares during the last quarter. Finally, True Wealth Design LLC boosted its holdings in shares of Sanofi by 1.9% during the 3rd quarter. True Wealth Design LLC now owns 13,828 shares of the company’s stock worth $742,000 after buying an additional 260 shares during the period. Institutional investors own 10.04% of the company’s stock.

Sanofi Stock Performance

Shares of NASDAQ:SNY traded down $1.41 on Thursday, hitting $48.69. 1,121,985 shares of the company were exchanged, compared to its average volume of 2,003,665. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. The company’s 50 day moving average price is $47.99 and its two-hundred day moving average price is $48.13. Sanofi has a one year low of $42.63 and a one year high of $55.72. The firm has a market capitalization of $123.17 billion, a price-to-earnings ratio of 24.47, a PEG ratio of 1.37 and a beta of 0.61.

Sanofi Increases Dividend

The company also recently declared an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be issued a $1.478 dividend. This is a boost from Sanofi’s previous annual dividend of $1.38. The ex-dividend date of this dividend is Thursday, May 9th. This represents a yield of 2.98%. Sanofi’s dividend payout ratio is 69.35%.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. TheStreet downgraded Sanofi from a “b” rating to a “c” rating in a research note on Friday, February 9th. Finally, Morgan Stanley started coverage on Sanofi in a research report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 price target on the stock. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $55.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.